One of the surprises at CROI 2016 was the first virological data from a new highly potent NRTI that in a slow-release formulation has the potential for annual dosing and that is undergoing research as both treatment and PrEP. In an oral late-breaker, Jay Grobler from Merck presented results from a dose-ranging study in macaques […]
New HIV Drug Has Potential for Weekly or Once-Yearly Dosing Read More »
CROI 2016 Conference Abstract Number: 795 Safety of Tenofovir Alafenamide in Renal Impairment Author(s): Anton Pozniak2, Jose R Arribas3, Samir K. Gupta4, Frank A. Post5, Anchalee Avihingsanon6, Gordon Crofoot7, Kenneth A. Lichtenstein8, Moti Ramgopal9, Ploenchan Chetchotisakd10, Marshall W. Fordyce11 Clinical Research, Gilead Sciences Inc, Foster City, CA, United States. 2 Chelsea and Westminster Hospital NHS Foundation Trust, London,
Switching HIV+ Patients From Stribld to Genvoya Improved Proteinuria but Not eGFR Read More »
HIV can defeat efforts to cripple it with CRISPR gene-editing technology, researchers say. And the very act of editing — involving snipping at the virus’s genome — may introduce mutations that help it to resist attack. At least half a dozen papers over the past three years have explored using the popular CRISPR–Cas9 gene editing
HIV Mutates Around Promising Gene Editing Technology (CRISPR-CAS 9) Read More »
HIV-related wasting can have long-term consequences People who suffered wasting in the past more vulnerable to frailty in later life Michael Carter Published: 30 November 2015 HIV-associated wasting can have a long-term impact on physical function and quality of life, according to research from the United States published in the online edition of AIDS. The research
HIV-related wasting can have long-term consequences Read More »
Men who have anal sex with men (MSM) are more likely to get anal HPVthan men who only have sex with women. Researchers estimate that the prevalence of anal HPV among men who only have sex with women is around 15% while anal HPV prevalence for MSM is around 60%. If you add HIV into the mix, infection risk
HPV and HIV: What You Need to Know About Anal Cancer (Video) Read More »
Forum on Aging With HIV: H. Pylori and HIV: What Do I Need to Know? (Editor’s Pick) Forum on Aging With HIV: H. Pylori and HIV: What Do I … I am very familiar with H. Pylori. I was diagnosed with it using a urea breath test 2
Best Posts on Aging with HIV from TheBody.com This Week Read More »
By Nelson Vergel. SalvageTherapies.org No one can deny that many patients can now suppress their HIV with effective antiretrovirals (ARVs) that cause fewer side effects. However, a vulnerable and often forgotten minority of people are still struggling with multi-drug resistant HIV (MDR-HIV) while they anxiously wait for access to lifesaving ARVs that would finally control
Webcast : Beyond the Berlin Patient- How Researchers Are Now Trying to Cure More HIV+ People By Nelson Vergel We all read headlines almost weekly about the latest HIV cure. After years of being exposed to these inflamed news reports, we may get desensitized to the fact that there is actually progress being made in
TRANSCRIPT FROM GOOGLE HANGOUT ON HIV PRE-EXPOSURE PROPHYLAXIS (PrEP) WITH DAMON JACOBS AND NELSON VERGEL Scott: Hello everybody. Scott Sillary here with Viral Marketing. I’m here with Nelson Vergel and Damon Jacobs. Welcome to the Power Hangout. It’s going to be fantastic. Nelson, tell us a little bit about what we’re going
The HIV Prevention Pill: A Free Webcast on July 29, 6:30 PM (EDT) Activists and educators Damon Jacobs and Nelson Vergel will answer questions about the use of Truvada for HIV Pre-Exposure Prophylaxis (PrEP) covering research facts, misconceptions and access of this highly effective prevention tool. This webcast is of interest to the lay person
The HIV Prevention Pill: A Free Webcast on July 29, 6:30 PM (EDT) Read More »
Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz? Frapsauce C, et al. Hum Reprod. 2015. Authors Frapsauce C1, Grabar S2, Leruez-Ville M3, Launay O4, Sogni P5, Gayet V6, Viard JP7, De Almeida M8, Jouannet P8, Dulioust E1. Author information 1Laboratoire de Biologie de la Reproduction, Hôpital Broca-Cochin-Hôtel Dieu, Assistance Publique-Hôpitaux de
Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz? Read More »
Video: HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial. Leading HIV activist Nelson Vergel raises hopes but also warns HIV salvage patients and their physicians about functional monotherapy risks in the Bristol-Meyers Squibb (BMS) new attachment inhibitor study (Fostemsavir, BMS-663068) currently enrolling (2015-2016). This innovative drug, along with Taimed’s ibalizumab, can be the
HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial. Read More »
